641 A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar hepatocellular carcinoma

• Hao Wang,
• Paul Thomas,
• Elizabeth M Jaffee,
• Mark Yarchoan,
• Jennifer Durham,
• Brian Ladle,
• Alex Thompson,
• Madalena Brancati,
• Christopher Thoburn,
• Zeal Kamdar,
• Marina Baretti,
• Julie Nauroth,
• Anna Ferguson,
• Paige Griffith,
• Allison Kirk,
• Neeha Zaidi,
• Amanda Huff,
• Won Ho,
• Mark Furth

Affiliations

Hao Wang

Department of General Surgery, Dongying People’s Hospital, Dongying, China

Paul Thomas

Department of Chemistry, Loughborough University, Loughborough, UK

Elizabeth M Jaffee

1Johns Hopkins University School of Medicine, Baltimore, MD, USA

Mark Yarchoan

3Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA

Jennifer Durham

1Johns Hopkins University School of Medicine, Baltimore, MD, USA

Brian Ladle

2Johns Hopkins University School of Medicine, Baltimore, MD, USA

Alex Thompson

4Johns Hopkins University, Baltimore, MD, USA

Madalena Brancati

1Johns Hopkins University School of Medicine, Baltimore, MD, USA

Christopher Thoburn

1Johns Hopkins University School of Medicine, Baltimore, MD, USA

Zeal Kamdar

2Johns Hopkins University School of Medicine, Baltimore, MD, USA

Marina Baretti

1Johns Hopkins University School of Medicine, Baltimore, MD, USA

Julie Nauroth

1Johns Hopkins University School of Medicine, Baltimore, MD, USA

Anna Ferguson

4Johns Hopkins University, Baltimore, MD, USA

Paige Griffith

4Johns Hopkins University, Baltimore, MD, USA

Allison Kirk

5St. Jude Children’s Research Hospital, Memphis, TN, USA

Neeha Zaidi

2Johns Hopkins Hospital, Baltimore, MD, USA

Amanda Huff

4Johns Hopkins University, Baltimore, MD, USA

Won Ho

4Johns Hopkins University, Baltimore, MD, USA

Mark Furth

6The Fibrolamellar Cancer Foundation, Greenwich, CT, USA